-
![BIO welcome reception]( "BIO2025: Sanofi R&D, FDA's Martin Makary, Paying For New Therapies")
BIO2025: Sanofi R&D, FDA's Martin Makary, Paying For New Therapies6/20/2025BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I attended.
-
![Adam Mendelsohn_Vivani]( "Companies To Watch: Vivani Medical")
Companies To Watch: Vivani Medical5/30/2025Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year. The company's lead program is an exenatide implant.
-
![Tolga_FTE_feature image]( "Promoting A Newly Approved Indication Against Established Competitors")
Promoting A Newly Approved Indication Against Established Competitors5/14/2025In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning Amvuttra's new ATTR-CM indication approval against competitors in the category.
-
![Brian Lortie FTE feature image]( "Building Uniquity Bio: Teams, Capital, And Strategy")
Building Uniquity Bio: Teams, Capital, And Strategy4/30/2025Brian Lortie, president and CEO at Uniquity Bio, offered up key insights on building teams, securing capital, and operating with efficiency during a recent Business of Biotech podcast recording.
-
![Ian Thompson_Amgen]( "Amgen's Ian Thompson On Leadership And A Global Mindset")
Amgen's Ian Thompson On Leadership And A Global Mindset4/8/2025Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's learned from working in global markets, and key pipeline highlights.
-
![Stacy Lindborg_Imunon]( "Companies To Watch: Imunon")
Companies To Watch: Imunon3/31/2025Imunon aims to shake up the standard of care in the frontline treatment of advanced ovarian cancer.
-
![Heather Turner_LB Pharma]( "A CEO With A General Counsel's Perspective")
A CEO With A General Counsel's Perspective2/28/2025LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous perspective on the CEO role.
-
![FCPA_Getty_1210948291]( "FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance")
FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance2/21/2025Criminal enforcement of the Foreign Corrupt Practices Act was paused on February 10 by a Trump administration executive order. That doesn't mean biopharmaceutical companies can backslide on compliance in global markets.
-
![Bobak Azamian]( "Where Are They Now? Tarsus Pharmaceuticals")
Where Are They Now? Tarsus Pharmaceuticals2/13/2025Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug.
Ben Comer
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.